Proactive Investors - Run By Investors For Investors

Sativa says 2019 first quarter revenues exceeding total revenues in the group’s first year of trading

Geremy Thomas, founder and chief executive officer of the medicinal cannabis and wellness cannabidiol (CBD) group said: "Sativa is delivering real revenues in a new and exciting sector"
Cannabis oils
The NEX-listed firm also said all resolutions were duly passed at today’s AGM including its proposed name change to Sativa Group PLC

Sativa Investments PLC (LON:SATI) has said its current financial year has begun well, with 2019 first quarter revenues exceeding total revenues in the group’s first year of trading.

In a brief trading statement to coincide with Wednesday’s annual general meeting, Geremy Thomas, founder and chief executive officer of the medicinal cannabis and wellness cannabidiol (CBD) group said: "Sativa is delivering real revenues in a new and exciting sector.  Key value drivers include manufacturing capability, testing, brands and distribution."

READ: Sativa Investments signs supply deal with Swiss cannabis oil producer Alponics

The Company also noted that, since the year-end, it has announced two overseas CBD oil take-off agreements, appointed RSM as auditor, appointed a Director of Regulatory Affairs and also a retail professional to oversee the roll-out of the Goodbody wellness centres, the first of which opens in Bath on 28 June 2019. 

In April 2019, the Company entered in to into a three-year research agreement with King's College London to research the impact of cannabinoids on inflammation and respiratory diseases.

The NEX-listed firm also said all resolutions were duly passed at today’s AGM including its proposed name change to Sativa Group PLC, which, now ratified by shareholders, will be completed within days.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full SATI profile View Profile

Sativa Group PLC Timeline

Related Articles

Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
cancer cell
Thu
The San Diego-based company has developed a patented liquid biopsy technology called Target Selector the detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA)
pills
April 13 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use